Search research articles
Contact Us
Filters
Showing results (121-130 of 188) with videos related to
Page
of 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H Segal, Theodore F Logan, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Neuro-Oncology Advances
|
May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasis
Alexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 188) with videos related to
Sort By:
Page
of 19
European Journal of Cancer (Oxford, England : 1990)
|
September 30, 2017
Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma
Omid Hamid, Igor Puzanov, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
October 27, 2022
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
Omid Hamid, Alberto A Chiappori, John A Thompson, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 1, 2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Neil H Segal, Theodore F Logan, F Stephen Hodi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
September 27, 2021
Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
Omid Hamid, Caroline Robert, Adil Daud, et al.
The New England Journal of Medicine
|
April 21, 2015
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V Long, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 29, 2017
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert, Antoni Ribas, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard, Michael S Gordon, Sunil Sharma, et al.
Neuro-Oncology Advances
|
May 10, 2024
POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with <i>BRAF</i> V600-mutant melanoma with brain metastasis
Alexander M Menzies, Georgina V Long, Amiee Kohn, et al.
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
Page
of 19